Using artificial cells to boost the immune response against cancer
Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
This study is exploring a new way to help your immune system fight cancer by using special artificial cells that can directly activate important immune cells in your body, making treatment easier and more effective for patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10913348 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of artificial cell that can activate the immune system's CD8+ T cells directly in the body to fight cancer. By using biocompatible materials, the project aims to create a more efficient and cost-effective method for cancer immunotherapy compared to traditional approaches. The artificial antigen presenting cells (aAPCs) will be designed to deliver the necessary signals for T cell activation without the need for complex laboratory procedures. Patients may benefit from a more accessible and effective treatment option for their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are eligible for adoptive cellular therapy and have specific tumor types that respond to CD8+ T cell activation.
Not a fit: Patients with cancers that do not involve CD8+ T cell responses or those who are not candidates for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more efficient and less expensive immunotherapy option for cancer patients.
How similar studies have performed: Previous research has shown promise in using artificial antigen presenting cells for T cell activation, indicating that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Shannon, Sydney Rose — Johns Hopkins University
- Study coordinator: Shannon, Sydney Rose
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.